Bristol-Myers Squibb Company / Celgene Corporation

Multiple Myeloma

36K US cases/yr · $27.8B Global Multiple Myeloma Market (2024) · ~58% 5-Year Survival Rate

Disease Overview

Multiple myeloma is the second most common hematologic malignancy with ~35,780 new US cases in 2024. The BMS-Celgene acquisition created the dominant MM franchise with IMiDs (Revlimid, Pomalyst), CAR-T (Abecma, Breyanzi), and bispecific antibodies in development.

Competitive Landscape

BMS dominates with Revlimid (declining due to generics), Pomalyst ($3.4B), and Abecma. J&J competes with Darzalex ($10B+), Tecvayli, and Carvykti. Novel modalities: CAR-T (ide-cel, cilta-cel), bispecifics (teclistamab, elranatamab), and CELMoDs (iberdomide). The MM market exceeds $27B globally.

Diffuse Large B-Cell Lymphoma

30K US cases/yr · $5.0B Global DLBCL Market (2024)

Disease Overview

DLBCL is the most common aggressive lymphoma with ~30,000 new US cases/year. While ~60% are cured with first-line R-CHOP, relapsed/refractory disease has been transformed by CAR-T therapy. Breyanzi (liso-cel) is BMS's key asset acquired via Celgene, now approved in 2L+ DLBCL.

Competitive Landscape

CAR-T: Yescarta (Gilead/Kite), Breyanzi (BMS), Kymriah (Novartis). Bispecifics: Columvi (Roche), Epkinly (AbbVie/Genmab). First-line: polatuzumab + R-CHP (Roche) replacing R-CHOP. Breyanzi's 2L approval was a key commercial driver reaching $720M in 2024.

Myelodysplastic Syndromes / Beta-Thalassemia

20K US cases/yr · $3.0B Global MDS/Anemia Market (2024) · $1.2B Reblozyl Revenue (2024)

Disease Overview

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias (anemia, neutropenia, thrombocytopenia), dysplastic bone marrow morphology, and a variable risk of progression to acute myeloid leukemia. NCI SEER estimates an age-adjusted MDS incidence of roughly 4 per 100,000 per year in the United States, corresponding to an estimated 10,000-15,000 newly diagnosed cases annually, with incidence rising sharply after age 70. Diagnosis requires bone marrow aspirate and biopsy with cytogenetics and increasingly next-generation sequencing of myeloid genes; risk stratification uses IPSS-R and the molecular IPSS-M to guide therapy. Management ranges from supportive care (transfusions, iron chelation, growth factors) in lower-risk disease through luspatercept for transfusion-dependent anemia, hypomethylating agents (azacitidine, decitabine) in higher-risk disease, and allogeneic hematopoietic stem cell transplantation for eligible patients, which remains the only curative option. Beta-thalassemia is a hereditary autosomal recessive hemoglobinopathy caused by mutations in the HBB gene that reduce or eliminate beta-globin production, leading to ineffective erythropoiesis, hemolysis, and a spectrum of severity from beta-thalassemia trait to transfusion-dependent beta-thalassemia major. Worldwide, tens of thousands of severely affected births occur annually, concentrated in Mediterranean, Middle Eastern, South Asian, and Southeast Asian populations; U.S. prevalence is smaller but clinically significant. Management includes chronic red cell transfusion with iron chelation, luspatercept for adults with transfusion-dependent disease, allogeneic HSCT, and gene therapy or gene-editing approaches.

Competitive Landscape

Reblozyl is the leading erythroid maturation agent for lower-risk MDS and beta-thalassemia. Geron's imetelstat received approval for lower-risk MDS. Inrebic (fedratinib) targets myelofibrosis, not MDS directly. Gene therapy (Casgevy, Lyfgenia) addresses beta-thalassemia via gene modification approaches.

Ulcerative Colitis

Competitive Landscape

Zeposia (ozanimod), an oral S1P receptor 1/5 modulator, enters a moderate-to-severe UC market defined by three established MOA classes and a rising oral challenger class. Anti-TNF biologics remain the volume leader: Remicade (infliximab) and Humira (adalimumab) are both approved for moderately-to-severely active UC, with Entyvio (vedolizumab), an alpha4-beta7 integrin antagonist from Takeda, dominating the gut-selective biologic segment and generating multi-billion-dollar global revenues. Anti-IL-12/23 and anti-IL-23 biologics form the second major class: Stelara (ustekinumab, J&J) gained UC approval in 2019 and Skyrizi (risankizumab, AbbVie) is advancing in IBD. The direct head-to-head competitive threat is the oral JAK-inhibitor class: Xeljanz (tofacitinib, Pfizer), approved for moderate-to-severe UC in 2018, and Rinvoq (upadacitinib, AbbVie), approved for UC in 2022, both compete for the same oral-convenience, biologic-experienced patient Zeposia targets. Within the S1P modulator class itself, Velsipity (etrasimod, Pfizer) was approved in October 2023 and is now Zeposia's closest in-class competitor. Commercial-lead read: Zeposia is differentiated on oral dosing and safety vs. biologics, but faces direct JAK and in-class S1P pressure post-2023.

Crohns Disease

Competitive Landscape

Zeposia (ozanimod) is FDA-approved in moderately to severely active ulcerative colitis and is under development in Crohn's disease (Phase 3 YELLOWSTONE program); the Crohn's competitive landscape is dominated by biologics and oral small molecules across multiple MOA classes. Anti-TNF: infliximab (Remicade, Janssen; biosimilars), adalimumab (Humira, AbbVie; biosimilars), and certolizumab pegol (Cimzia, UCB) are FDA-approved in Crohn's and remain high-volume incumbents despite biosimilar erosion. Anti-integrin: vedolizumab (Entyvio, Takeda), gut-selective anti-alpha-4-beta-7, is FDA-approved in CD and UC and is the dominant non-anti-TNF biologic by sales; natalizumab (Tysabri, Biogen) is approved with REMS. Anti-IL-12/23: ustekinumab (Stelara, Janssen; biosimilars emerging) is FDA-approved in CD. Selective anti-IL-23p19: risankizumab (Skyrizi, AbbVie) is FDA-approved in moderately to severely active CD per ADVANCE/MOTIVATE/FORTIFY; mirikizumab (Omvoh, Lilly) is FDA-approved in CD (2024) per VIVID-1; guselkumab (Tremfya, Janssen) is FDA-approved in CD (2025) per GALAXI/GRAVITI. JAK inhibitors: upadacitinib (Rinvoq, AbbVie, JAK1-selective) is FDA-approved in CD per U-EXCEL/U-EXCEED/U-ENDURE. S1P receptor modulators (direct MOA class): ozanimod Crohn's is pending; etrasimod (Velsipity, Pfizer) is FDA-approved in UC only. For a commercial lead, anti-IL-23p19 uptake and upadacitinib are the principal franchise threats.

Mantle Cell Lymphoma

Competitive Landscape

Breyanzi (lisocabtagene maraleucel) is FDA-approved for relapsed/refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy including a BTK inhibitor, competing against another CAR-T and a deep bench of targeted agents. Anti-CD19 CAR-T (direct MOA competitor): brexucabtagene autoleucel (Tecartus, Kite/Gilead) is FDA-approved in r/r MCL post-BTKi per ZUMA-2 and is Breyanzi's principal CAR-T rival; it was first-to-market in MCL (July 2020). Covalent BTK inhibitors: ibrutinib (Imbruvica, AbbVie/J&J, US MCL indication voluntarily withdrawn 2023), acalabrutinib (Calquence, AstraZeneca), and zanubrutinib (Brukinsa, BeiGene) are the frontline/relapsed oral standards; the SHINE trial (ibrutinib-BR first-line in older patients) and ECHO/TRIANGLE expanded BTKi positioning. Non-covalent BTK inhibitor: pirtobrutinib (Jaypirca, Lilly) is FDA-approved in r/r MCL after prior BTKi, the direct post-BTKi competitor to CAR-T. BCL-2 inhibitor: venetoclax (Venclexta, AbbVie/Genentech) is used off-label in MCL, commonly in combination. Proteasome inhibitor: bortezomib (Velcade, Takeda; generics) is FDA-approved in r/r MCL. Immunomodulator: lenalidomide (Revlimid, BMS) is FDA-approved in r/r MCL. Bispecific antibodies (CD20xCD3): glofitamab (Columvi, Roche) received FDA accelerated approval in r/r MCL (2025). For a commercial lead, Tecartus, pirtobrutinib, and emerging bispecifics are the principal share threats post-BTKi.

CLL / Small Lymphocytic Lymphoma

Competitive Landscape

Breyanzi (lisocabtagene maraleucel) is FDA-approved for relapsed/refractory CLL/SLL after at least two prior lines including a BTK inhibitor and a BCL-2 inhibitor, competing in a market dominated by oral targeted agents in earlier lines. Covalent BTK inhibitors: ibrutinib (Imbruvica, AbbVie/J&J), acalabrutinib (Calquence, AstraZeneca), and zanubrutinib (Brukinsa, BeiGene) are FDA-approved in CLL/SLL and form the backbone of frontline and second-line therapy; zanubrutinib demonstrated superiority over ibrutinib in ALPINE. Non-covalent BTK inhibitor: pirtobrutinib (Jaypirca, Lilly) is FDA-approved in CLL/SLL after prior BTK and BCL-2 therapy and is the direct cross-MOA competitor to Breyanzi in the post-BTKi/BCL-2 setting. BCL-2 inhibitor: venetoclax (Venclexta, AbbVie/Genentech) in combination with obinutuzumab (first-line) or rituximab (relapsed) is a time-limited standard; obinutuzumab (Gazyva, Genentech, anti-CD20) underpins frontline CIT-free regimens. Anti-CD20 monoclonal antibodies: rituximab (Rituxan, Genentech) and biosimilars remain in combination backbones. PI3K inhibitors: idelalisib (Zydelig, Gilead) and duvelisib (Copiktra, Secura Bio) have restricted use due to toxicity. Other CAR-T: brexucabtagene autoleucel (Tecartus, Kite/Gilead) is not approved in CLL. For a commercial lead, Breyanzi's CLL opportunity is narrow post-BTKi/BCL-2 third-line-plus, with pirtobrutinib the most direct cross-MOA share threat.

Myelofibrosis

Competitive Landscape

Inrebic (fedratinib) is FDA-approved for intermediate-2 or high-risk primary or secondary myelofibrosis (MF), competing in a JAK inhibitor-dominated field with cytopenia-tailored differentiation. JAK inhibitors (direct MOA class): ruxolitinib (Jakafi, Incyte/Novartis) is the market-leading JAK1/2 inhibitor and category-defining first-line standard with CV and spleen-volume outcomes data from COMFORT-I/II; pacritinib (Vonjo, Sobi) is FDA-approved for MF with platelets <50x10^9/L (PERSIST/PACIFICA), targeting the cytopenic subgroup that cannot tolerate ruxolitinib; momelotinib (Ojjaara, GSK) is FDA-approved for MF with anemia (MOMENTUM/SIMPLIFY-1), with JAK1/2 plus ACVR1 activity addressing transfusion dependence. BET inhibitor: pelabresib (CPI-0610, Novartis) is in Phase 3 (MANIFEST-2) as a ruxolitinib combination partner. Anti-anemia/telomerase inhibitor: imetelstat (Rytelo, Geron) is FDA-approved in MDS (not MF) but advancing in MF (IMpactMF). Other anemia-directed: luspatercept (Reblozyl, BMS/Merck) is FDA-approved in MDS and beta-thalassemia; MF trials ongoing. Cytoreductive/supportive: hydroxyurea, interferon (pegylated interferon alfa-2a/ropeginterferon alfa-2b for earlier MPN), danazol, and ESAs are used for specific symptom management. Allogeneic hematopoietic stem cell transplant remains the only curative option. For a commercial lead, Inrebic's franchise threat is bracketed above by Jakafi (frontline share) and below by momelotinib (anemia) and pacritinib (severe thrombocytopenia), compressing the eligible second-line patient pool.

Relapsing Multiple Sclerosis

Competitive Landscape

Zeposia (ozanimod) is FDA-approved for relapsing forms of multiple sclerosis (RMS), competing across oral small molecules and high-efficacy biologic MOA classes. S1P receptor modulators (direct MOA class): fingolimod (Gilenya, Novartis; generics), siponimod (Mayzent, Novartis, S1P1/5-selective, approved for active secondary progressive MS), and ponesimod (Ponvory, J&J/Vanda) are FDA-approved; fingolimod generics materially pressure class pricing. Anti-CD20 monoclonal antibodies (highest-efficacy class by share gains): ocrelizumab (Ocrevus, Roche/Genentech) is FDA-approved in RMS and PPMS and is the dominant high-efficacy biologic; ofatumumab (Kesimpta, Novartis) is a subcutaneous anti-CD20 approved in RMS; ublituximab (Briumvi, TG Therapeutics) is FDA-approved in RMS; rituximab (Rituxan) is used off-label. Anti-alpha-4 integrin: natalizumab (Tysabri, Biogen) is FDA-approved in RMS under a REMS. Fumarates: dimethyl fumarate (Tecfidera, Biogen; generics), diroximel fumarate (Vumerity, Biogen), and monomethyl fumarate (Bafiertam, Banner) are oral incumbents. Pyrimidine synthesis inhibitor: teriflunomide (Aubagio, Sanofi; generics) is FDA-approved in RMS. Interferons and glatiramer acetate (Copaxone, Teva; generics) anchor the legacy platform-injectable segment. Selective immune reconstitution: cladribine (Mavenclad, Merck KGaA) is FDA-approved in RMS. BTK inhibitors: tolebrutinib (Sanofi), evobrutinib, and fenebrutinib are in late-stage MS trials. For a commercial lead, anti-CD20 class share gains and fingolimod generic pricing are Zeposia's principal threats.